Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

Woman smelling the scent from an open bottle

Loss of sense of smell is a frequent symptom following COVID-19 infection. Although for a significant proportion of patients, the loss is only temporary and their sense of smell recovers relatively quickly, for others, the problem can persist and can have a major impact on quality of life.

Cochrane ENT has been awarded £34,011 of funding by the NIHR for a project on the ‘Prevention and treatment of persisting olfactory dysfunction after COVID-19 infection’.

Cochrane ENT will use the funding to complete a suite of Cochrane living systematic reviews to identify interventions that have been used to prevent or treat loss of smell following COVID-19 infection. The reviews will assess the effectiveness of interventions, as well as any adverse effects they may have. These living systematic reviews will be updated as and when new research becomes available.

This project is one of a number of COVID-19 projects that have been funded by the NIHR as part of its Recovery and Learning call, totalling £5.5m in funding, to help better manage current and future waves of the COVID-19 pandemic and investigate its long-term impacts on the health and care system beyond the acute phase.

You can find more information on the NIHR website

Find out more about Cochrane’s response to COVID

Meet the Chief Investigator

Similar stories

Prostate cancer AI diagnosis tool begins evaluation in Oxford

New artificial intelligence software that can help to spot prostate cancer is being trialled by researchers at Oxford University Hospitals (OUH) NHS Foundation Trust.

NDS SITU host first ever Surgical Trials Showcase

The first ever showcase of the Surgical Intervention Trials Unit, Nuffield Department of Surgical Sciences (NDS SITU) was hosted on Monday 23 January 2023 at the Richard Doll Building on Old Road Campus, Oxford, and also online.

Mr Gurdeep S. Mannu awarded Cancer Research UK Clinician Scientist Fellowship

Many congratulations to Mr Gurdeep S. Mannu who has been awarded a five-year Cancer Research UK Clinician Scientist Fellowship.

Blog posts

Marathon challenge for Prostate Cancer UK

Runners of all abilities started 2023 by challenging themselves to run 26.2 miles across January to fundraise for Prostate Cancer UK as part of the charity’s Run the Month: Marathon Edition.

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.